Close
What would you like to look for?
Site search

30 May 2022

VISCHER has advised ADVANZ PHARMA, a specialty pharmaceutical company headquartered in London, on all Swiss legal aspects of its USD 450m acquisition of the ex-US business of Intercept Pharmaceuticals, spanning from due diligence to transactional document advice. White & Case acted as lead counsel in this transaction. The acquisition is expected to be completed during the third quarter 2022, subject to customary legal and regulatory closing conditions.

The transaction is actively supported by ADVANZ PHARMA's owner Nordic Capital, a leading private equity investor with extensive experience and expertise in the global healthcare market, which acquired ADVANZ PHARMA in June 2021.

The VISCHER team led by partner Dr. Adrian Dörig (Corporate Finance) comprised Dr. Peter Kühn (Counsel, Corporate/M&A), Anna Salm (Junior Associate, Corporate/M&A) and Gian Geel (Associate, Employment).

Categories: Mergers & Acquisitions, Deals & Cases

Authors

You are currently offline. Some pages or content may fail to load.